JP2003527079A5 - - Google Patents

Download PDF

Info

Publication number
JP2003527079A5
JP2003527079A5 JP2000615413A JP2000615413A JP2003527079A5 JP 2003527079 A5 JP2003527079 A5 JP 2003527079A5 JP 2000615413 A JP2000615413 A JP 2000615413A JP 2000615413 A JP2000615413 A JP 2000615413A JP 2003527079 A5 JP2003527079 A5 JP 2003527079A5
Authority
JP
Japan
Prior art keywords
nucleotides
nucleic acid
protein
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000615413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003527079A (ja
Filing date
Publication date
Priority claimed from PCT/US1999/023573 external-priority patent/WO2000022430A2/en
Priority claimed from GB0004695A external-priority patent/GB0004695D0/en
Application filed filed Critical
Priority claimed from PCT/US2000/005928 external-priority patent/WO2000066791A1/en
Publication of JP2003527079A publication Critical patent/JP2003527079A/ja
Publication of JP2003527079A5 publication Critical patent/JP2003527079A5/ja
Pending legal-status Critical Current

Links

JP2000615413A 1999-04-30 2000-03-08 ナイセリアゲノム配列およびそれらの使用方法 Pending JP2003527079A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13206899P 1999-04-30 1999-04-30
US60/132,068 1999-04-30
PCT/US1999/023573 WO2000022430A2 (en) 1998-10-09 1999-10-08 Neisseria genomic sequences and methods of their use
US99/23573 1999-10-08
GB0004695A GB0004695D0 (en) 2000-02-28 2000-02-28 Protein expression
GB0004695.3 2000-02-28
PCT/US2000/005928 WO2000066791A1 (en) 1999-04-30 2000-03-08 Neisseria genomic sequences and methods of their use

Publications (2)

Publication Number Publication Date
JP2003527079A JP2003527079A (ja) 2003-09-16
JP2003527079A5 true JP2003527079A5 (enExample) 2007-04-05

Family

ID=27255563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000615413A Pending JP2003527079A (ja) 1999-04-30 2000-03-08 ナイセリアゲノム配列およびそれらの使用方法

Country Status (13)

Country Link
US (1) US20070219347A1 (enExample)
EP (2) EP1605061A1 (enExample)
JP (1) JP2003527079A (enExample)
CN (2) CN101033467A (enExample)
AT (1) ATE430207T1 (enExample)
AU (1) AU780308B2 (enExample)
BR (1) BR0010361A (enExample)
CA (1) CA2371032A1 (enExample)
DE (1) DE60042114D1 (enExample)
DK (1) DK1185691T3 (enExample)
ES (1) ES2323845T3 (enExample)
MX (1) MXPA01011047A (enExample)
WO (1) WO2000066791A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0935659A1 (en) 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
AU2109700A (en) 1999-01-22 2000-08-07 Smithkline Beecham Biologicals (Sa) Novel compounds
PT1163343E (pt) 1999-03-12 2010-02-23 Glaxosmithkline Biolog Sa Polipéptidos antigénicos de neisseria meningitidis, polinucleótidos e anticorpos protectores correspondentes
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
EP1252182B1 (en) 2000-01-25 2012-06-20 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
JP5511117B2 (ja) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
GB0107219D0 (en) * 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
RU2322451C2 (ru) * 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
RU2355704C2 (ru) * 2001-04-17 2009-05-20 Новартис Вэксинс Энд Диагностикс, Инк Моноклональное антитело, направленное против gna33 пептида, и его применение
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002355197A1 (en) 2001-07-27 2003-02-17 Chiron Srl Meningococcus adhesins nada, app and orf 40
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7807181B2 (en) 2002-03-20 2010-10-05 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
DE20321889U1 (de) * 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
WO2006096527A2 (en) * 2005-03-04 2006-09-14 Diversa Corporation Nucleic acids and proteins and methods for making and using them
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CA3059650C (en) * 2017-05-10 2023-12-19 Global Bioenergies Improved methods for producing isobutene from 3-methylcrotonic acid
WO2019018744A1 (en) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
US20220081707A1 (en) * 2018-07-25 2022-03-17 The Trustees Of Indiana University Diagnostic assay for a strain of neisseria meningitidis
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN113136444B (zh) * 2021-05-10 2024-04-19 临沂大学 医用食品中海氏肠球菌的微滴数字pcr检测方法
CN116162140B (zh) * 2022-07-19 2025-09-09 四川大学华西医院 一种幽门螺杆菌重组抗原蛋白SecG及其制备方法与应用
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025077785A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98837A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Pharmaceutical compositions comprising proteins from the outer membrane of neisseria meningitidis and their use to increase the immune response
EP0467714A1 (en) * 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
CA2050635A1 (en) * 1990-07-19 1992-01-20 Allen I. Oliff Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties, and vaccines containing same
US6472518B1 (en) * 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
JP2004511201A (ja) * 1998-10-09 2004-04-15 カイロン コーポレイション ナイセリアゲノム配列およびそれらの使用方法

Similar Documents

Publication Publication Date Title
JP2003527079A5 (enExample)
JP2005511076A5 (enExample)
JP2004511201A5 (enExample)
RU2007139915A (ru) Haemophilus influenzae типа в
JP2002542827A5 (enExample)
JP2008538183A5 (enExample)
JP2008525033A5 (enExample)
RU2009102815A (ru) Полипептиды из neisseria meningitidis
JP2004501618A5 (enExample)
JP2004513622A5 (enExample)
JP2003500040A5 (enExample)
JP2008508859A5 (enExample)
JP2002510649A5 (enExample)
EP2292646A3 (en) Small Streptococcus pyogenes antigens and their use
RU2006144093A (ru) Полипептиды нетипируемой haemophilus influenzae
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
JP2013523718A5 (enExample)
WO2001034809A3 (en) Staphylococcus epidermidis nucleic acids and proteins
JP2003504062A5 (enExample)
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
JP2010508276A5 (enExample)
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
CA2370814A1 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
JP2003530872A5 (enExample)
JP2002525081A5 (enExample)